2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 386

Long-Term Efficacy and Safety of Adalimumab in Pediatric Patients with Enthesitis Related Arthritis

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster I: Juvenile Idiopathic Arthritis, Uveitis

9:00AM-11:00AM: Abstract Number: 743

Long-Term Hydroxychloroquine Therapy and Low-Dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 859

Long-Term Outcomes of Renal Artery Involvement in Takayasu Arteritis

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 612

Long-Term Sustainability of TNF-Blocker Injection Spacing in Rheumatoid Arthritis: Results of a 3-Year Long-Term Observational Follow-up of a Tapering randomised Controlled Trial

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 72

Longitudinal Expression of CXCL10 in Psoriasis Patients That Develop Psoriatic Arthritis

Genetics, Genomics and Proteomics - Poster I

9:00AM-11:00AM: Abstract Number: 170

Low Baseline Temperature and Low Basal Flow Can be Related to the Paradoxical Raynaud’s Phenomenon in Hand Perfusion Scintigraphy

Imaging of Rheumatic Diseases - Poster I: Ultrasound and Emerging Technologies

9:00AM-11:00AM: Abstract Number: 795

Low Disease Activity in Systemic Lupus Erythematosus: An Achievable Goal?

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 659

Low Dose IL-2 Therapy Can Restore the Balance of Th17 and Treg Cells in Refractory Patients with Sjogren’s Syndrome

Sjögren's Syndrome - Poster I: Translational Science

9:00AM-11:00AM: Abstract Number: 677

Low Functional Relevance of Radiographic Spinal Progression in Patients with Early Axial Spondyloarthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 841

Low Nucleoside Triphosphate Pyrophosphohydrolase Activity Contributes to Pathologic Mineralization in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I

9:00AM-11:00AM: Abstract Number: 869

Low Numbers of CD16+ Monocytes Predict Shorter Time to Relapse in Polymyalgia Rheumatica

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 513

Low Serum 25-Hydroxyvitamin D Level Is Not Associated with Decreased Bone Mass or Bone Quality in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 6

Lower Omega-3 Fatty Acid Biomarkers Are Associated with Inflammatory Arthritis in a Population Positive for Anti-Citrullinated Protein Antibodies

Epidemiology and Public Health - Poster I

9:00AM-11:00AM: Abstract Number: 594

Maintenance of Improvements in Patients’ Physical Function, Workplace and Household Productivity, and Reduction in Caregiver Burden with 2 Years of Certolizumab Pegol Treatment in DMARD-Naive, Early RA Patients with Severe Progressive Disease

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 239

Malignancies in Korean Patients with Immunoglobulin G4-Related Disease

Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].